Beijing Chao-Yang Hospital, Capital Medical University

Running trials

• Not yet recruiting

  Study of YKST02 in Adults With Relapsed or Refractory Multiple Myeloma

  NCT07695740· Phase 2· Excyte Biopharma Ltd· Source

• Not yet recruiting

  A Phase 3 Study of Povorcitinib Phosphate in Chinese Adults With Nonsegmental Vitiligo

  NCT07865312· Phase 3· Dermavon Holdings Limited· Source

• Recruiting

  SKCD in Early Relapsed/Refractory Multiple Myeloma

  NCT07931391· Phase 2· Beijing Chao Yang Hospital· Source

• Not yet recruiting

  Diagnostic Performance of an AI-Based Multi-Omics Model for Early Lung Cancer

  NCT07882628· Beijing Chao Yang Hospital· Source

• Recruiting

  RESET-COPD Cohort: Real-Time Monitoring and Early Warning in COPD Patients Receiving Home NPPV

  NCT07701096· Beijing Chao Yang Hospital· Source

• Not yet recruiting

  Treatment Strategy for Patients With RA-ILD

  NCT07643038· Phase 4· Chinese SLE Treatment And Research Group· Source

• Recruiting

  Safety and Efficacy of KSVCBD Injection in Multiple Myeloma Expressing CD19 and/or BCMA

  NCT07620275· Phase 1· Chinese PLA General Hospital· Source

• Recruiting

  Cardiopulmonary Exercise Testing-based High-intensity Interval Training For Improving Heart Failure With Preserved Ejection Fraction

  NCT07693049· Peking University Third Hospital· Source

• Recruiting

  A Clinical Trial on the Efficacy and Safety of TQH3906 in the Treatment of Systemic Lupus Erythematosus

  NCT07509892· Phase 2· Chia Tai Tianqing Pharmaceutical Group Co., Ltd.· Source

• Recruiting

  A Phase Ib/IIa Study of INT-210 Capsules in Participants With Active Ulcerative Colitis

  NCT07692165· Phase 1/2· Innatus Therapeutics (Shanghai) Co., Ltd.· Source

• Not yet recruiting

  Clinical Study of TQB2934 Injection in Relapsed/Refractory Multiple Myeloma

  NCT07569757· Phase 3· Chia Tai Tianqing Pharmaceutical Group Co., Ltd.· Source

• Recruiting

  A Study to Compare the PK Characteristics, Safety, Tolerability, and Immunogenicity of HLX15-SC With DARZALEX FASPRO® in Combination With Lenalidomide and Dexamethasone (Rd) in Transplant-ineligible Patients With Newly Diagnosed Multiple Myeloma

  NCT07477587· Phase 1· Shanghai Henlius Biotech· Source

• Not yet recruiting

  Efficacy Heterogeneity of Lactobacillus Paracasei LC19 on Type 2 Diabetes

  NCT07520305· Beijing Chao Yang Hospital· Source

• Recruiting

  Smartwatch-based Intervention for Cardiovascular Health (SWITCH)

  NCT07372729· Beijing Anzhen Hospital· Source

• Recruiting

  Transpulmonary Pressure-guided Mechanical Ventilation Strategy in Right Ventricular Protection in Patients With ARDS

  NCT07490925· Beijing Chao Yang Hospital· Source

• Recruiting

  Study to Assess Safety and Efficacy of HDP-101 in Chinese Patients With Relapsed or Refractory Multiple Myeloma

  NCT07529782· Phase 1· Hangzhou Zhongmei Huadong Pharmaceutical Co., Ltd.· Source

• Recruiting

  Real-world Study of Aflibercept 8 mg in nAMD

  NCT07640997· Peking University People's Hospital· Source

• Recruiting

  Alternating Regimen of VA and Low-dose CHA in the Treatment of Unfit Newly Diagnosed AML

  NCT07172204· Phase 2· First Affiliated Hospital of Zhejiang University· Source

• Recruiting

  A Study to Learn About the Study Medicine Called PF-07275315 in People With Moderate-To-Severe Asthma

  NCT06977581· Phase 2· Pfizer· Source

• Recruiting

  ICP-332 in Subjects With Non-segmental Vitiligo

  NCT07047612· Phase 2/3· Beijing InnoCare Pharma Tech Co., Ltd.· Source

• Recruiting

  Investigation and Classification of Treatable Traits in Patients With Chronic Airway Diseases

  NCT07472738· Beijing Chao Yang Hospital· Source

• Not yet recruiting

  A Multicenter, Open-label, Prospective Phase III Clinical Trial to Evaluate INR101 Injection for PET/CT Imaging in Participants With Suspected Recurrent Prostate Cancer After Radical Treatment

  NCT06922929· Phase 3· Yunhe Pharmaceutical (Tianjin) Co., Ltd· Source

• Not yet recruiting

  Phase III Clinical Trial to Evaluate INR101 Injection for PET/CT Imaging in Patients With Prostate Cancer.

  NCT06922903· Phase 3· Yunhe Pharmaceutical (Tianjin) Co., Ltd· Source

• Recruiting

  Riociguat-Discontinue Effects on Right HEART in CTEPH (RED-HEART)

  NCT06922240· Phase 3· Suqiao Yang· Source

• Active, not recruiting

  A Phase III Study in Subjects With Primary Open Angle Glaucoma or Ocular Hypertension in China

  NCT06666855· Phase 3· Santen Pharmaceutical Co., Ltd.· Source

• Recruiting

  Long-term Impact of Inhaled Tobramycin for Pseudomonas Aeruginosa Eradication in Bronchiectasis (ERASE II)

  NCT06760273· Shanghai Pulmonary Hospital, Shanghai, China· Source

• Active, not recruiting

  A Follow-up Study to Test Long-term Treatment With Nerandomilast in People With Pulmonary Fibrosis Who Took Part in a Previous Study With Nerandomilast

  NCT06238622· Phase 3· Boehringer Ingelheim· Source

• Recruiting

  Remote Ischemic Conditioning for Acute Ischemic Stroke Treated With Mechanical Thrombectomy（RECAST-MT）

  NCT06559241· Phase 3· Capital Medical University· Source

• Recruiting

  A Study of YKST02 in Participants With Relapsed or Refractory Multiple Myeloma

  NCT06574568· Phase 1· Excyte Biopharma Ltd· Source

• Not yet recruiting

  Henagliflozin's Impact on Prediabetes Remission

  NCT06448130· Phase 4· Shandong Provincial Hospital· Source

• Recruiting

  Effects of Intraoperative Targeted Temperature Management on Incidence of Postoperative Delirium and Long-term Survival

  NCT06256354· Peking University First Hospital· Source

• Active, not recruiting

  Evolve China PMCF Study

  NCT06368622· Stryker Neurovascular· Source

• Active, not recruiting

  A Phase III Study of Eque-cel in Subjects With Len-refractory RRMM (FUMANBA-03)

  NCT06464991· Phase 3· Nanjing IASO Biotechnology Co., Ltd.· Source

• Recruiting

  The Cohort Study for Asthma in China

  NCT05937334· Beijing Chao Yang Hospital· Source

• Recruiting

  Treatment of Chinese Participants With B-Cell Malignancies With BGB-16673, a Bruton Tyrosine Kinase-Targeted Protein-Degrader

  NCT05294731· Phase 1/2· BeOne Medicines· Source

• Active, not recruiting

  Long-term Efficacy and Safety Study of GV-971

  NCT05181475· Phase 4· Green Valley (Shanghai) Pharmaceuticals Co., Ltd.· Source

• Active, not recruiting

  A Study of Zanidatamab in Combination With Chemotherapy Plus or Minus Tislelizumab in Patients With HER2-positive Advanced or Metastatic Gastric and Esophageal Cancers

  NCT05152147· Phase 3· Jazz Pharmaceuticals· Source

• Active, not recruiting

  A Study of NINLARO® in Chinese Adults With Multiple Myeloma

  NCT05013190· Takeda· Source

• Recruiting

  A Phase 1b/2 Study of Sonrotoclax (BGB-11417) as Monotherapy and in Various Combinations With Dexamethasone Plus Carfilzomib, Dexamethasone Plus Daratumumab, and Dexamethasone Plus Pomalidomide in Multiple Myeloma

  NCT04973605· Phase 1/2· BeOne Medicines· Source

• Active, not recruiting

  Phase I-II, FIH, TROP2 ADC, Advanced Unresectable/Metastatic Solid Tumors, Refractory to Standard Therapies (KL264-01)

  NCT04152499· Phase 1/2· Klus Pharma Inc.· Source

• Active, not recruiting

  A Study of Sasanlimab in People With Non-muscle Invasive Bladder Cancer

  NCT04165317· Phase 3· Pfizer· Source

• Active, not recruiting

  eXalt3: Study Comparing X-396 (Ensartinib) to Crizotinib in ALK Positive Non-Small Cell Lung Cancer (NSCLC) Patients

  NCT02767804· Phase 3· Xcovery Holdings, Inc.· Source

• Recruiting

  The Chinese Familial Alzheimer's Network

  NCT03657732· Capital Medical University· Source

• Recruiting

  China Cognition and Aging Study

  NCT03653156· Capital Medical University· Source

Recruiting at the same time

How many trials recruit for the same indication here at once. A count, not a rating.

• Multiple myeloma8 recruiting
• Asthma3 recruiting
• Alzheimer disease2 recruiting
• COPD2 recruiting
• Prostate cancer2 recruiting
• Type 2 diabetes2 recruiting
• Vitiligo2 recruiting
• Acute myeloid leukaemia1 recruiting
• Bronchiectasis1 recruiting
• Childhood cancers1 recruiting
• Chronic lymphocytic leukaemia1 recruiting
• Follicular lymphoma1 recruiting
• Heart failure1 recruiting
• High blood pressure1 recruiting
• Lung cancer1 recruiting
• Lupus (SLE)1 recruiting
• Macular degeneration1 recruiting
• Mantle cell lymphoma1 recruiting
• Mild cognitive impairment1 recruiting
• Obesity1 recruiting
• Pulmonary arterial hypertension1 recruiting
• Rheumatoid arthritis1 recruiting
• Stroke1 recruiting
• Ulcerative colitis1 recruiting
• Vascular dementia1 recruiting

Closed trials

• Recruiting

  Efficacy, Safety, Pharmacokinetics of ICP-488 in Patients With Moderate to Severe Plaque Psoriasis

  NCT06842199· Phase 3· Beijing InnoCare Pharma Tech Co., Ltd.· Source

• Completed

  Invasive Vagus Nerve Stimulation Paired With Rehabilitation After Stroke

  NCT07736573· Beijing Chao Yang Hospital· Source

• Completed

  Efficacy of Lactobacillus Paracasei LC19 on Type 2 Diabetes

  NCT06639425· Beijing Chao Yang Hospital· Source

• Completed

  A Study to Test Whether BI 1819479 Improves Lung Function in People With Idiopathic Pulmonary Fibrosis (IPF)

  NCT06335303· Phase 2· Boehringer Ingelheim· Source

• Completed

  Budesonide/Formoterol Inhalation Powder in Adults With Asthma

  NCT07790159· Phase 3· Shanghai Xin Huanghe Pharmaceutical Co., Ltd.· Source

• Completed

  A Study to Test Whether Survodutide (BI 456906) Helps Chinese People Living With Overweight or Obesity to Lose Weight

  NCT06214741· Phase 3· Boehringer Ingelheim· Source

• Completed

  A Clinical Study of JS005 in Patients With Ankylosing Spondylitis

  NCT06250062· Phase 2· Shanghai Junshi Bioscience Co., Ltd.· Source

• Completed

  A Study to Test the Effect of Survodutide (BI 456906) on Cardiovascular Safety in People With Overweight or Obesity (SYNCHRONIZE™ - CVOT)

  NCT06077864· Phase 3· Boehringer Ingelheim· Source

• Completed

  An Open-Label Study of Aficamten for Chinese Patients With Symptomatic oHCM

  NCT06116968· Phase 3· Corxel Pharmaceuticals· Source

• Completed

  Tobramycin Inhalation Solution for Pseudomonas Aeruginosa Eradication in Bronchiectasis

  NCT06093191· Phase 4· Jin-Fu Xu· Source

• Completed

  A Study of SPH3127 in the Treatment of Mild to Moderate Ulcerative Colitis

  NCT05770609· Phase 2· Shanghai Pharmaceuticals Holding Co., Ltd· Source

• Completed

  Evaluation of the Effect of Injectable Neucardin on Cardiac Function and Reversal Ventricular Remodeling in Patients With Chronic Systolic Heart Failure

  NCT05949801· Phase 3· Zensun Sci. & Tech. Co., Ltd.· Source

• Terminated

  Treatment Efficacy of Systemic Corticosteroids in AECOPD Patients With Higher Blood Eosinophil Levels

  NCT05059873· Phase 4· Capital Medical University· Source

• Completed

  Efficacy and Safety of Fruquintinib in Combination With Sintilimab in Advanced Renal Cell Carcinoma (FRUSICA-2)

  NCT05522231· Phase 2/3· Hutchmed· Source

• Completed

  Efficacy Evaluation Study of BAT5906 and Lucentis® in Patients With Macular Degeneration

  NCT05439629· Phase 3· Bio-Thera Solutions· Source

• Completed

  Phase 3 Trial to Evaluate the Efficacy and Safety of Aficamten Compared to Placebo in Adults With Symptomatic oHCM

  NCT05186818· Phase 3· Cytokinetics· Source

• Terminated

  Efficacy and Safety of KBP-5074 in Uncontrolled Hypertension and Moderate or Severe Chronic Kidney Disease (CKD)

  NCT04968184· Phase 3· Novo Nordisk A/S· Source

• Completed

  A Study of Evaluating the Safety and Efficacy of ATG-010, Bortezomib, and Dexamethasone (SVd) Versus Bortezomib and Dexamethasone (Vd) in Patients With Relapsed or Refractory Multiple Myeloma (RRMM)

  NCT04939142· Phase 3· Antengene Corporation· Source

• Completed

  A Research Study Investigating Semaglutide in People With Early Alzheimer's Disease (EVOKE Plus)

  NCT04777409· Phase 3· Novo Nordisk A/S· Source

• Completed

  Clinical Study of HMPL-689 for Relapsed/Refractory Marginal Zone Lymphoma and Follicular Lymphoma

  NCT04849351· Phase 2· Hutchison Medipharma Limited· Source

• Completed

  Real-world Study on Edoxaban Treatment for Patients With Non-valvular Atrial Fibrillation in China

  NCT04747496· Daiichi Sankyo· Source

• Completed

  EMPACT-MI: A Study to Test Whether Empagliflozin Can Lower the Risk of Heart Failure and Death in People Who Had a Heart Attack (Myocardial Infarction)

  NCT04509674· Phase 3· Boehringer Ingelheim· Source

• Completed

  A Study of TQB2450 Injection Combined With Anlotinib Hydrochloride Capsule in Subjects With Advanced Endometrial Cancer

  NCT04574284· Phase 2· Chia Tai Tianqing Pharmaceutical Group Co., Ltd.· Source

• Completed

  A Study of Ninlaro in Real World Clinical Practice in China

  NCT04328662· Takeda· Source

• Completed

  A Study of Baricitinib (LY3009104) in Adults With Severe or Very Severe Alopecia Areata

  NCT03899259· Phase 3· Eli Lilly and Company· Source

• Completed

  TJ202, Lenalidomide and Dexamethasone vs. Lenalidomide and Dexamethasone in Subjects With Relapsed or Refractory Multiple Myeloma

  NCT03952091· Phase 3· TJ Biopharma Co., Ltd.· Source

• Completed

  Tislelizumab in Combination With Chemotherapy as First-Line Treatment in Adults With Inoperable, Locally Advanced or Metastatic Gastric, or Gastroesophageal Junction Carcinoma

  NCT03777657· Phase 3· BeiGene· Source

• Completed

  LUX-Head&Neck 3: Afatinib (BIBW2992) Versus Methotrexate for the Treatment of Recurrent and/or Metastatic Head and Neck Squamous Cell Cancer After Platinum Based Chemotherapy

  NCT01856478· Phase 3· Boehringer Ingelheim· Source

Conditions

Diseases this institution publishes on or runs trials for.

• Multiple myeloma35 works · 13 trials
• COPD26 works · 3 trials
• Brain aneurysm8 works · 1 trial
• Vitiligo5 works · 2 trials